In 60 adults with grass pollen allergic rhinoconjunctivitis, three intralymphatic injections of grass allergoid with microcrystalline tyrosine cut combined symptom and medication score vs placebo by 33% in 2022 (non-significant) and 50% in 2023 (p<0.05); no severe adverse events.
RCTn = 60
Šošić et al. Efficacy and Safety of Intralymphatic Immunotherapy With Grass Allergoid and Microcrystalline Tyrosine: A Double-Blind Randomised Placebo-Controlled Trial